Cardiovascular Disease

Successfully Executing Cardiovascular Outcomes Trials

The Cardiovascular teams at BBMCT are highly skilled in the scientific methodology, standard of care, evolving regulatory requirements and operational considerations that are necessary to bring drugs and devices that treat or prevent heart disease to market. Our extensive experience in cardiovascular studies paired with our proven track record of success in the cardiovascular CRO industry ensures the flexibility to adapt to the unique needs of each cardiovascular trial.

In order to ensure success, we help our clients:

• Effectively plan and conduct cardiovascular studies for drug/device and cardiac safety
• Efficiently conduct large cardiovascular endpoint trials that demand rigorous safety requirements
• Seamlessly integrate cardiovascular trials with metabolic/endocrinology projects.

As your cardiovascular CRO, we deliver rapid study start up timelines, on time deliverables, proactive risk management and quality data, achieving study timelines within projected budgets. We understand that small biotech companies need a partner who can complement their limited staff and be sensitive to budget restrictions.

We are experienced in working with smaller biotech companies in a variety of models and can easily adapt to your needs. Our individual cardiovascular group provides a small CRO feel with all the benefits of being a large CRO. We understand the nuances of successfully running a global, cardiovascular outcomes trial (CVOT). That’s why we have staff in medical leadership, project management, clinical operations, pharmacovigilance and statistics with CVOT experience who can execute trials using proven effective strategies.

British BioMedicine Clinical Trials (BBMCT)

Our Cardiovascular Clinical Experience

We have extensive experience in cardiovascular clinical trials and research, including new therapies such as stem cells, HFpEF, HFrEF, SGLT-2 inhibitors and large, global CVOTs. Our experts have created strategy plans that expedite timelines and deliver superb data quality while adhering tightly to sponsors’ budgets. We have worked on indications for cardiovascular drugs in the following areas:

• Acute coronary syndrome
• Angina pectoris
• Arrhythmias
• Cardiothoracic surgery
• Deep vein thrombosis
• Diabetes
• Dyslipidemia
• Heart failure
• Hypertension
• Hyperlipidemia
• Ischemic heart disease
• Obesity
• Peripheral arterial disease
• Pulmonary hypertension
• Renal failure (acute and chronic)
• Venous thromboembolism (VTE)

Capturing High-Quality Cardiovascular Clinical Data Safely, With Global Consistency

Our web-based electronic endpoint adjudication system is specially tailored for long-term, large-scale, global cardiovascular clinical trials and research. We use it together with our innovative data monitoring strategies, which employ risk-based techniques encouraged by regulatory authorities to improve patient safety while providing cost efficiencies.